Companies: 10,795·Total market cap: $144.5T
Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

ACXPNASDAQHealthcare● Active
$1.69
+$0.07(+4.32%)
Market Cap$2678613
P/E Ratio
52W High$21
52W Low$1.326
SEC Filings

Acurx Pharmaceuticals, Inc. (ACXP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001736243 · ACXP · NASDAQ · as of Jun 9, 2026

Filing snapshot

232
Total Filings
424B3
Latest Form
2026-05-12
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001736243 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001104659-26-027052
Primary Document
acxp-20251231x10k.htm
Source: data.sec.gov · CIK 0001736243 · Accession 0001104659-26-027052

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-11
8-KCurrent Report
FORM 8-K
2026-04-16Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
424B3424B3
424B3
2026-05-12
View
424B3424B3
424B3
2026-05-12
View
EFFECTEFFECT
EFFECT
2026-05-11
View
EFFECTEFFECT
EFFECT
2026-05-11
View
10-QQuarterly Report
10-Q
2026-05-11
View
S-1IPO Registration Statement
FORM S-1
2026-05-04
View
S-1IPO Registration Statement
FORM S-1
2026-05-04
View
DD
D
2026-04-29
View
8-KCurrent Report
FORM 8-K
2026-04-16
View
424B5424B5
424B5
2026-04-16
View
S-8Employee Stock Plan Registration
FORM S-8
2026-03-12
View
10-KAnnual Report
10-K
2026-03-12
View
8-KCurrent Report
FORM 8-K
2026-03-09
View
EFFECTEFFECT
EFFECT
2026-02-11
View
424B3424B3
424B3
2026-02-11
View
Showing 1–15 of 181 filingsForm 4 / 144 hidden· 232 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001736243  |  Exchange: NASDAQ · Healthcare

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has submitted 232 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001736243, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Acurx Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Acurx Pharmaceuticals, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical ACXP 10-K annual reports are available from 2018 through 2026.

Investors researching Acurx Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ACXP SEC Filings · 8 questions

Acurx Pharmaceuticals, Inc. (ACXP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 232 filings and access original documents at no cost. Acurx Pharmaceuticals, Inc.'s CIK is 0001736243.

ACXP SEC filingsAcurx Pharmaceuticals, Inc. SEC documentsfind ACXP 10-K